business
Teva Presents Positive Post Hoc Data For TEV-'749 For Schizophrenia; FDA Decision In Q4 '26
Teva Pharmaceutical Industries Ltd. (TEVA), a generic drugs company, on Friday presented positive post-hoc data from the Phase 3 SOLARIS trial for TEV-'749 in treating schizophrenia.
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
Major banks raise interest rates after RBA lifts cash rate to highest since 2011
abc.net.au
Back carriages on Tangara train services shut for school holidays amid security breaches
abc.net.au
Madonna beats Taylor Swift in MTV awards showdown
abc.net.au
Rewards programs and insurance perks in firing line after changes to bank surcharging rules
abc.net.au
From vines to vegetation, property becomes safe haven for an endangered bird species
abc.net.au